Precision oncology company focused on developing non-invasive cancer diagnostics using blood-based tests.
Guardant Health, Inc. is a pioneering precision oncology company renowned for its comprehensive suite of blood tests, data analytics, and precision oncology solutions offered both domestically and globally. Central to its offerings are the Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests designed for patients with advanced stage cancer. These tests provide crucial insights into genomic alterations, aiding clinicians in making informed treatment decisions based on the unique genetic profiles of individual patients.
The company is at the forefront of developing innovative diagnostic technologies, including the LUNAR-2 test, aimed at early detection of colorectal cancer in asymptomatic individuals who meet eligibility criteria. Guardant Health also introduced GuardantConnect, an integrated software solution that links patients tested with the Guardant360 assay to relevant clinical trials, facilitating personalized treatment approaches.
Guardant Health's commitment to advancing cancer diagnostics extends to the Guardant Reveal Test, which supports treatment selection for early-stage cancer patients undergoing neoadjuvant and adjuvant therapies. Additionally, the company offerrs Guardant360 tissue genotyping and Guardant-19, a test used for detecting the novel coronavirus, highlighting its versatility in addressing diverse healthcare needs.
In collaboration with biopharmaceutical companies and medical institutions, Guardant Health provides essential development services, including companion diagnostic development, regulatory approval, clinical study setup, monitoring, testing support, and kit fulfillment. These strategic initiatives underscore Guardant Health's mission to transform cancer care through cutting-edge technologies and strategic partnerships. Founded in 2011 and headquartered in Redwood City, California, Guardant Health continues to drive innovation and expand its impact in precision oncology globally.